Moxifloxacin

C. diff Risk

High

Oral Bioavailability

Good (70 to 90%)

Approximate Cost

$0.78 (PO)
$14.41 (IV)

Spectrum Of Activity

Dosing

400mg IV/PO daily

General Information

Common Usage

  • Pneumonia including CAP, HAP, aspiration

  • Some intra-abdominal infections

  • CNS infections

Drug Monitoring

Monitor QTc in patients with increased risk

Adverse Effects

  • QTc prolongation

  • Dysglycemia

  • Rash

  • Tendinopathy and rupture

  • GI upset

  • Weakness exacerbation in myasthenia gravis

  • CNS toxicity including confusion, psychosis

Major Interactions

QTc prolongation - Increased risk with other agents that prolong QTc

Divalent cations including Ca, Mg - Decreased absorption

Warfarin - Increased INR

Rifampin - Decrease moxifloxacin levels

Tablet/Capsule Strengths

SPECIAL AUTHORIZATION REQUIRED

Additional Information

IV Administration
Premixed 400 mg bags; infuse over 60 min
Premixed bags are not compatible with pumps used in community IV program

EH Prescribing Restrictions
None (Pharmacist review of IV therapy)

NLPDP Status (PO)
Special Authorization required

Tablets can be crushed and given via NG route; No liquid formulation available
Bioavailability 85-90%

Pharmacology

Antimicrobial class: Fluoroquinolone

Pregnancy category: C

Average serum half life: 12 hours

Biliary penetration: Therapeutic

CSF penetration: Therapeutic

Lung penetration: Therapeutic

Urine penetration: Poor